Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease - Contacts and Locations

Home

Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease

This study has been completed.

Study NCT00010387. Last updated on September 8, 2008. Information provided by Office of Rare Diseases (ORD)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00010387

Locations


United States, Maryland
	Johns Hopkins Oncology Center
	Baltimore, Maryland, United States, 21231

Sponsors and Collaborators

Johns Hopkins University

Investigators


Study Chair:	Robert A. Brodsky	Johns Hopkins University